Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Hematology · Chronic Myelomonocytic Leukemia

How Is CMML Progression to AML Detected by Doctors?

At a Glance

Doctors assess CMML progression by tracking blood-count trends, symptoms, transfusion needs, and immature leukemia cells. Traditionally, 20% or more blast equivalents in blood or bone marrow indicates AML, but certain genetic findings can allow AML diagnosis below 20%; repeat marrow and genetic tests help confirm the change.

In this answer

6 sections

01

How Often Will I Be Monitored?

02

Warning Signs in Your Blood Counts

03

Physical Symptoms and Extramedullary Disease

04

The “In-Between” Stage: Advanced CMML

05

The Definitive Tests

06

When to Seek Urgent Care

Doctors detect the progression of chronic myelomonocytic leukemia (CMML) or its transformation to acute myeloid leukemia (AML) by tracking trends in your blood counts, symptoms, and specialized laboratory tests.

The traditional medical threshold for AML transformation is reached when blasts (immature leukemia cells) and promonocytes (slightly more developed, but still abnormal cells) make up 20% or more of the cells in your blood or bone marrow [1] [2]. Hematopathologists count blasts and promonocytes together as “blast equivalents.” However, under current classification systems (like the WHO or ICC), certain AML-defining genetic mutations can sometimes allow a diagnosis of AML even if the blast count is below 20% [3] [4].

How Often Will I Be Monitored?

There is no single monitoring schedule for everyone. Your follow-up intervals are individualized based on your CMML risk level, current blood counts, treatments, and any recent changes [5].

Warning Signs in Your Blood Counts

Routine complete blood counts (CBC) and differential tests (which count the different types of white blood cells) are primary tools for monitoring CMML. Doctors look for trends over time rather than a single abnormal result. Finding changes prompts further evaluation—though it is important to note that infections, bleeding, or medication side effects can also cause these changes. Warning signs that your disease may be progressing include:

  • Rising blasts or promonocytes: An increase in these immature cells circulating in your peripheral blood (blood drawn from a vein) indicates higher-risk disease [6] [7].
  • Worsening cytopenias: A progressive drop in your healthy red blood cells (anemia) or platelets (thrombocytopenia) can signal that abnormal cells are crowding out healthy bone marrow [8].
  • Increasing transfusion needs: Needing red blood cell or platelet transfusions more frequently may suggest the disease is advancing [8].
  • New or worsening leukocytosis: A rapid, uncontrolled rise in your total white blood cell count can indicate that the disease is becoming more proliferative (growing faster) [9] [5].

Physical Symptoms and Extramedullary Disease

Sometimes CMML cells accumulate outside the bone marrow, a condition called extramedullary disease.

  • Splenomegaly (Enlarged Spleen): CMML cells can gather in the spleen, causing it to enlarge. This might make you feel full after eating only a small amount or cause discomfort in your upper left abdomen [10] [11].
  • Tissue involvement: CMML can sometimes infiltrate the skin, lymph nodes, liver, or gums [12]. Involvement in the central nervous system or lungs is very rare, but can occur [13] [14].

Why symptoms alone do not prove AML: Worsening fatigue, new bleeding, or an enlarging spleen can happen while the disease is still technically CMML. While these symptoms mean the disease may be becoming more aggressive and requires medical attention, they do not automatically mean you have AML.

The “In-Between” Stage: Advanced CMML

It is important to know that a blast count doesn’t have to reach 20% to be serious. If your blasts and promonocytes rise to between 10% and 19% in the bone marrow, this is often classified as advanced CMML (such as CMML-2) [1] [13]. This intermediate stage warrants prompt hematology review and potential treatment changes, as the risk of transforming to AML is very high.

The Definitive Tests

When blood counts or symptoms suggest progression, doctors use specialized tests to see exactly what is happening at a cellular and genetic level.

  • Blood-Smear Review: A specialist looks at your blood under a microscope to manually count blasts, promonocytes, and other immature cells [15].
  • Flow Cytometry (Immunophenotyping): This test identifies specific proteins on the surface of your cells to characterize abnormal cell populations and confirm their lineage [16] [17].
  • Repeat Bone Marrow Examination: A new bone marrow biopsy and aspirate are usually recommended to accurately count blasts inside the marrow, though sometimes an adequate blood sample is enough to establish a diagnosis [13].
  • Cytogenetics (Karyotyping): This looks at the chromosomes inside your leukemia cells. Acquiring new chromosomal abnormalities—especially a “complex karyotype” (multiple major genetic mistakes)—is strongly tied to AML progression [18] [19].
  • Molecular Testing (NGS): Next-Generation Sequencing (NGS) checks for specific DNA mutations. Over time, CMML cells can acquire new mutations (such as in the RAS pathway, FLT3, or NPM1 genes) [20] [21]. Finding new mutations shows “clonal evolution” (the cancer is changing). While a new mutation alone doesn’t prove AML transformation, it helps your doctor assess your risk and may uncover new targeted treatment options [22] [23].

When to Seek Urgent Care

Because CMML affects your immune system and blood clotting, complications can become dangerous quickly. Do not wait for your next routine appointment if you experience severe symptoms.

Call your oncology clinic immediately for:

  • A fever of 100.4°F (38°C) or higher, chills, or other signs of infection [24].
  • New or unusual bruising, or minor bleeding that takes longer to stop than usual [25].
  • Markedly reduced urine output.

Go to the emergency room or call emergency services for:

  • Severe shortness of breath or sudden, severe chest pain [26] [27].
  • Uncontrolled bleeding [26].
  • Sudden, severe pain in your upper left abdomen (which could indicate a spleen complication) [28] [29].
  • Sudden severe headaches, fainting, or sudden confusion [14].

Common questions in this guide

How do doctors tell whether CMML is getting worse?
Doctors compare complete blood counts and white-cell differentials over time, looking for rising immature cells, worsening anemia or low platelets, increasing transfusion needs, or a rapidly rising white-cell count. They also consider symptoms and examination findings. One abnormal result does not prove progression because infection, bleeding, or medication effects can cause similar changes.
What blast count suggests that CMML has transformed into AML?
Traditionally, AML transformation is diagnosed when blasts and promonocytes together make up 20% or more of the cells in the blood or bone marrow. Current classification systems can define AML below 20% in some cases when specific AML-defining genetic changes are present. Doctors confirm the result with appropriate laboratory and bone marrow testing.
Can CMML be advanced even if the blast count is below 20%?
Yes. When blasts and promonocytes make up 10% to 19% of bone marrow cells, CMML may be classified as advanced disease, such as CMML-2. This situation carries a high risk of AML transformation and warrants prompt review by a hematology team.
Which tests are used to check for CMML progression or AML transformation?
Doctors may review a blood smear, use flow cytometry to identify abnormal cell populations, and repeat a bone marrow biopsy and aspirate to count immature cells. Chromosome testing can find new or complex abnormalities, while next-generation sequencing can detect new mutations and show how the leukemia is changing.
Does an enlarged spleen or worsening fatigue mean that CMML has become AML?
Not necessarily. An enlarging spleen, fatigue, bleeding, or other new symptoms can signal more active or advanced CMML, but symptoms alone do not establish AML transformation. Blood or marrow cell counts and specialized testing are needed to determine what is happening.
When should someone with CMML call the clinic or seek emergency care?
Call the oncology clinic promptly for a temperature of 100.4°F (38°C) or higher, chills, unusual bruising or bleeding, or markedly reduced urine output. Seek emergency help for severe shortness of breath, sudden severe chest or upper-left abdominal pain, uncontrolled bleeding, severe headache, fainting, or sudden confusion.

Related questions

How Do CMML Risk Scores Differ? CPSS-Mol, Mayo, iCPSS What Is CMML Life Expectancy and AML Risk by Group? Can a CMML Risk Score Change Over Time? What to Know Can Past Cancer Treatment or Chemical Exposure Cause CMML? Can Diet, Exercise, or Supplements Treat CMML? What to Know
Show more
Can I Work, Exercise, and Travel During CMML Treatment? How Common Is CMML, and Who Develops This Blood Cancer? How Do Doctors Tell Reactive Monocytosis From CMML? How Do Dysplastic CMML and Proliferative CMML Differ? How Is CMML Different From CML, MDS and Other Blood Cancers? How Long Must Monocytosis Last Before CMML Diagnosis? How Should I Interpret My CMML Risk Score Results? Is CMML Inherited? Should My Family Get Genetic Testing? What Causes CMML? Did I Do Anything to Cause My CMML? What Do CMML Chromosome and Mutation Tests Mean for You? What Is Monocyte Repartitioning Flow Cytometry for CMML? What Is the Difference Between CMML-1 and CMML-2? Treatment What Is the WHO vs ICC Difference in CMML Diagnosis? Why Do I Need a Bone Marrow Biopsy for CMML Diagnosis?

Get notified when new evidence is published on chronic monocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

    Patnaik MM, Tefferi A

    American journal of hematology 2024; (99(6)):1142-1165 doi:10.1002/ajh.27271.

    PMID: 38450850
  2. 2

    Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study.

    Foucar K, Hsi ED, Wang SA, et al.

    International journal of laboratory hematology 2020; (42(4)):418-422 doi:10.1111/ijlh.13212.

    PMID: 32297416
  3. 3

    Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

    Lachowiez CA, Asimomitis G, Bernard E, et al.

    Blood cancer discovery 2025; (6(5)):425-436 doi:10.1158/2643-3230.BCD-25-0047.

    PMID: 40608896
  4. 4

    Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

    Castaño-Díez S, Álamo JR, López-Guerra M, et al.

    The oncologist 2025; (30(2)) doi:10.1093/oncolo/oyae246.

    PMID: 39349391
  5. 5

    Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

    Itzykson R, Fenaux P, Bowen D, et al.

    HemaSphere 2018; (2(6)):e150 doi:10.1097/HS9.0000000000000150.

    PMID: 31723789
  6. 6

    Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.

    Patnaik MM, Wassie EA, Lasho TL, et al.

    American journal of hematology 2015; (90(5)):411-6 doi:10.1002/ajh.23962.

    PMID: 25645147
  7. 7

    Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia.

    Rivera Duarte A, Armengol Alonso A, Sandoval Cartagena E, Tuna Aguilar E

    Clinical lymphoma, myeloma & leukemia 2017; (17(8)):532-538 doi:10.1016/j.clml.2017.06.029.

    PMID: 28842140
  8. 8

    Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

    Elena C, Gallì A, Such E, et al.

    Blood 2016; (128(10)):1408-17 doi:10.1182/blood-2016-05-714030.

    PMID: 27385790
  9. 9

    Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.

    Aguirre LE, Ball S, Jain A, et al.

    Clinical lymphoma, myeloma & leukemia 2025; (25(9)):661-671 doi:10.1016/j.clml.2025.03.016.

    PMID: 40254502
  10. 10

    Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.

    Tremblay D, Rippel N, Feld J, et al.

    The oncologist 2021; (26(5)):406-421 doi:10.1002/onco.13769.

    PMID: 33792103
  11. 11

    Chronic myelomonocytic leukemia diagnosis and management.

    Chan O, Renneville A, Padron E

    Leukemia 2021; (35(6)):1552-1562 doi:10.1038/s41375-021-01207-3.

    PMID: 33714974
  12. 12

    Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease.

    Ahmidouch M, Deshpande P, Salib C, et al.

    Leukemia 2026; (40(7)):1343-1351 doi:10.1038/s41375-026-02966-7.

    PMID: 42045559
  13. 13

    A Heart of Myeloid: Extramedullary Chronic Myelomonocytic Leukemia-2 Presenting as a Myeloid Sarcoma of the Pericardium Causing Recurrent Pericardial Effusions.

    Frisch A, Boyapati R, Parikh R, et al.

    Journal of medical cases 2025; (16(7)):248-253 doi:10.14740/jmc5144.

    PMID: 40727113
  14. 14

    Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature.

    Bernat AL, Priola SM, Elsawy A, et al.

    Expert review of neurotherapeutics 2018; (18(5)):371-377 doi:10.1080/14737175.2018.1464391.

    PMID: 29658352
  15. 15

    Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML).

    Crymes A, Evans MG, Jeyakumar D, et al.

    Case reports in hematology 2024; (2024()):5584297 doi:10.1155/crh/5584297.

    PMID: 39734743
  16. 16

    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.

    Montalban-Bravo G, Kanagal-Shamanna R, Li Z, et al.

    British journal of haematology 2023; (203(4)):581-592 doi:10.1111/bjh.19060.

    PMID: 37608562
  17. 17

    Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.

    Kern W, Westers TM, Bellos F, et al.

    Cytometry. Part B, Clinical cytometry 2023; (104(1)):51-65 doi:10.1002/cyto.b.22105.

    PMID: 36416672
  18. 18

    Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia.

    Tang G, Fu B, Hu S, et al.

    American journal of hematology 2015; (90(10)):882-7 doi:10.1002/ajh.24108.

    PMID: 26148174
  19. 19

    Cumulative incidence and prognostic factors for leukemic transformation in chronic myelomonocytic leukemia: a competing risk analysis.

    Huang J, Zheng C, Liu Y, et al.

    BMC cancer 2026; (26(1)).

    PMID: 42310629
  20. 20

    Genomic determinants of chronic myelomonocytic leukemia.

    Patel BJ, Przychodzen B, Thota S, et al.

    Leukemia 2017; (31(12)):2815-2823 doi:10.1038/leu.2017.164.

    PMID: 28555081
  21. 21

    Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison.

    Kao HW, Kuo MC, Ou CW, et al.

    The Journal of pathology 2025; (265(4)):437-447 doi:10.1002/path.6396.

    PMID: 39905935
  22. 22

    AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

    Castaño-Díez S, López-Guerra M, Zugasti I, et al.

    Blood advances 2025; (9(1)):39-53 doi:10.1182/bloodadvances.2024013648.

    PMID: 39388660
  23. 23

    Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.

    Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, et al.

    Cancers 2022; (14(17)) doi:10.3390/cancers14174107.

    PMID: 36077644
  24. 24

    A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients.

    Zhang L, Ge R, Pan D, et al.

    Frontiers in pharmacology 2024; (15()):1265840 doi:10.3389/fphar.2024.1265840.

    PMID: 38756378
  25. 25

    Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.

    Jachiet V, Moulis G, Hadjadj J, et al.

    Haematologica 2021; (106(5)):1414-1422 doi:10.3324/haematol.2020.272559.

    PMID: 33626866
  26. 26

    Severe Acute Kidney Injury Associated with Transformation of Chronic Myelomonocytic Leukemia into Acute Myeloid Leukemia: A Case Report.

    Lee SW, Kim MS, Kim YJ, et al.

    Journal of clinical medicine 2024; (13(2)) doi:10.3390/jcm13020494.

    PMID: 38256628
  27. 27

    [Pulmonary infiltrates associated with chronic elevation of blood circulating monocytes].

    Batton R, Demeyere M, Chaloin L, et al.

    La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.09.018.

    PMID: 42919714
  28. 28

    Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report.

    Pelkey LJ, Graham DM, Zakem MH, Muza-Moons MM

    Cureus 2022; (14(2)):e22422 doi:10.7759/cureus.22422.

    PMID: 35228982
  29. 29

    Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

    Pophali P, Horna P, Lasho TL, et al.

    American journal of hematology 2018; (93(11)):1347-1357 doi:10.1002/ajh.25246.

    PMID: 30105755

This page explains how clinicians monitor CMML progression and possible AML transformation for informational purposes only and does not constitute medical advice. Your hematology team should interpret your results and tell you when to seek urgent care.